Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of hepatitis B antibody persistence after HB-AS02V versus Fendrix vaccination in dialysis patients
2005-004056-13Phase 3Completed
- Sponsor
- Henogen
- Start
- Jan 2007
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of adjuvanted hepatitis B vaccine HB-AS02V and Hepatitis B vaccine in hepatitis B (HBV) (2 arms), sponsored by Henogen. Primary endpoints: Persistence of anti-HBs antibodies at Month 12, Persistence of anti-HBs antibodies at Month 24 and 1 more. Started Jan 2007; status: completed.
02
Drugs
adjuvanted hepatitis B vaccine HB-AS02VHepatitis B vaccine
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on 2005-004056-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004056-13.